stilbenes and Cystitis--Interstitial

To assess the efficacy of a micronized-palmitoylethanolamide-polydatin (m-PEA-Pol) based product on chronic pelvic pain and severity of other symptoms in interstitial cystitis/bladder pain syndrome (IC/BPS) patients refractory to conventional therapies.. A pilot, open-label bicentric study was carried out involving 32 IC/BPS patients. Chronic, oral m-PEA-Pol treatment lasted 6 months. Bladder pain was evaluated using the visual analog scale, while changes from baseline in other urinary symptoms were evaluated by means of the O'Leary-Sant Interstitial Cystitis Symptom and Problem Index and the Pelvic Pain and Urgency/Frequency (PUF) symptom scale questionnaires. The generalized linear mixed model was used to evaluate significant mean changes across time.. A significant and progressive reduction of pain intensity was observed during m-PEA-Pol treatment (. These data highlight the potential benefit of m-PEA-Pol in patients with rare pathology such as IC/BPS and confirm the good safety profile of micronized PEA-based products.

Topics: Administration, Oral; Adult; Aged; Amides; Chronic Pain; Cystitis, Interstitial; Ethanolamines; Female; Glucosides; Humans; Male; Middle Aged; Pain Measurement; Palmitic Acids; Pelvic Pain; Pilot Projects; Stilbenes; Urination